Lung cancer trial aims to uncover secrets of drug resistance
NCT ID NCT03969823
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why some lung cancers stop responding to the drug osimertinib. Researchers will analyze the genetic makeup of tumors from 148 patients with advanced EGFR-mutant lung cancer who take osimertinib as their first treatment. The goal is to identify resistance mechanisms and track safety and survival outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Osimertinib (Tagrisso)
- What this could lead to
- If successful, this could reveal new ways to overcome drug resistance, potentially leading to better treatments for EGFR-mutant lung cancer.
- What could go wrong
- This is an early-stage, single-arm study focused on understanding resistance, not proving a new treatment works. Results may not lead to immediate clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Borame Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.